Clinical Trial Update: A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of CS-101 for beta-thalassemia major, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major

Drugs mentioned

• CS-101

Snippet

Sponsor: CorrectSequence Therapeutics Co., Ltd | Conditions: β-thalassemia Major | Phase 2 | Status: NOT_YET_RECRUITING